Hepatitis C virus transmission by intravenous immunoglobulin.

[1]  L. Frangeul,et al.  Testing for HCV-RNA in commerical intravenous immunoglobulins , 1993, The Lancet.

[2]  M. Kazatchkine.  Clinical applications of intravenous immunoglobulin therapy: edited by Peng Lee Yap, Churchill Livingstone, 1992. £40 (ix + 270 pages) ISBN 0443 045887 , 1993 .

[3]  H. Suomela.  Inactivation of viruses in blood and plasma products. , 1993, Transfusion medicine reviews.

[4]  S. Yei,et al.  Partitioning of hepatitis C virus during Cohn‐Oncley fractionation of plasma , 1992, Transfusion.

[5]  E. Holmes,et al.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. , 1992, The Journal of general virology.

[6]  J. Muller,et al.  HCV confirmatory testing of blood donors. , 1991, Lancet.

[7]  M. Roggendorf,et al.  Long-term persistence of hepatitis C virus antibodies in a single source outbreak. , 1991, Journal of hepatology.

[8]  C. Stornello.  Transmission of hepatitis B via human bite , 1991, The Lancet.

[9]  C. Fonatsch,et al.  Chromosomal aberrations during interferon therapy for chronic myelogenous leukemia. , 1991, The New England journal of medicine.

[10]  P. Simmonds,et al.  Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users , 1990, The Lancet.

[11]  G. D'offizi,et al.  Hepatitis C virus antibodies in gammaglobulin , 1990, The Lancet.

[12]  R. Tedder,et al.  Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates , 1990, The Lancet.

[13]  R. Tedder,et al.  Detection by PCR of hepatitis C virus in factor VIII concentrates , 1990, The Lancet.

[14]  S. Urbaniak,et al.  Transmission of Non‐A, Non‐B Hepatitis by pH4‐Treated Intravenous Immunoglobulin , 1989, Vox sanguinis.

[15]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[16]  C. Cunningham-Rundles,et al.  Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. , 1988, The American journal of medicine.

[17]  P. Yap,et al.  The viral safety of intravenous immunoglobulin. , 1987, The Journal of infection.

[18]  O. Weiland,et al.  NON-A, NON-B HEPATITIS AFTER INTRAVENOUS GAMMAGLOBULIN , 1986, The Lancet.

[19]  L. Hammarström,et al.  IgM PRODUCTION IN HYPOGAMMAGLOBULINAEMIC PATIENTS DURING NON-A, NON-B HEPATITIS , 1986, The Lancet.

[20]  P. Yap,et al.  NON-A, NON-B HEPATITIS AND INTRAVENOUS IMMUNOGLOBULIN , 1985, The Lancet.

[21]  H. Kingdon,et al.  NON-A, NON-B HEPATITIS AND INTRAVENOUS IMMUNOGLOBULIN , 1985, The Lancet.

[22]  H. Thomas,et al.  NON-A, NON-B HEPATITIS OCCURRING IN AGAMMAGLOBULINAEMIC PATIENTS AFTER INTRAVENOUS IMMUNOGLOBULIN , 1984, The Lancet.

[23]  R. Lane,et al.  NON-A, NON-B HEPATITIS FROM INTRAVENOUS IMMUNOGLOBULIN , 1983, The Lancet.